stockanalysis – Page 14

Bristol-Myers Squibb Company(BMY)：$50 per share is a good buying opportunity

Bristol-Myers Squibb(BMY)Q1 2024 Introduction Bristol-Myers Squibb Company(BMY) continues to operate in one segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global…

stockanalysis January 17, 2024

Pharmaceutical

AstraZeneca PLC(AZN): 2022 financial report and Q3 2023 earnings analysis

AstraZeneca PLC(AZN) in fiscal 2022 has six reportable products sales: Oncology($14.6 billion ), Cardiovascular, Renal & Metabolism($9.18 billion ), Respiratory & Immunology($5.76 billion ), Vaccines & Immune Therapies($4.7 billion ),…

stockanalysis January 14, 2024

Pharmaceutical

Eli Lilly and Company(LLY)’market capitalization amount to approximately $600 billion ,and even PE is more than 100 times, which mean shareholders need to earn back their capital over a hundred year.

Introduction Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis,…

stockanalysis January 11, 2024

Pharmaceutical

Johnson & Johnson(JNJ)’ financial analysis and value

Description of the Company and Business Segments Johnson & Johnson and its subsidiaries (the Company) have approximately 152,700 employees worldwide engaged in the research and development, manufacture and sale of…

stockanalysis January 9, 2024

Pharmaceutical

AbbVie(ABBV) is worth about $200 billion or $113.2 per share ,which is a good buy opportunity.

Company Overview(from AbbVie(ABBV)’s 2022 form 10k) AbbVie(ABBV)is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience…

stockanalysis January 7, 2024

Pharmaceutical

Amgen(AMGN) reported $19.99 billion in revenues in the nine months ended September 30,2023 and $19.4 billion in revenues in the nine months end September 30,2022.

Investment advice We reckon that $168 per share is a good buy point. Introduction Amgen(AMGN)operate in six commercial areas: inflammation, oncology/hematology, bone health, cardiovascular (CV) disease, nephrology and neuroscience. …

stockanalysis January 5, 2024

Pharmaceutical

Novartis AG(NVS) reported net sales of $34 billion in the nine months to September 30, 2023, up from $31.6 billion in the nine months to September 30,2022.

Summary We reckon that Novartis AG(NVS)’ stock price was overestimated ,and $73 per share is a good buy point. Introduction Novartis AG(NVS) is a multinational group of company specializing in…

stockanalysis January 2, 2024

Pharmaceutical

Regeneron Pharmaceuticals: A Financial Analysis

Summary Regeneron Pharmaceuticals has much money and the debt ratio is very lower. The firm’ financial performance fluctuate substantially, which trigger the fluctuation of the stock price. The company value…

stockanalysis December 30, 2023

Pharmaceutical

Gilead Sciences, Inc.: A Closer Look at Financial Performance and Growth Strategies

Summary Gilead Sciences, inc. is a cash cow. We reckon that $80 billion market value for the company is reasonable . The acquisitions is an expansion model, which is unpredictable.…

stockanalysis December 29, 2023